| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;91:1975-1980.)
© 1995 American Heart Association, Inc.
Articles |
Natural History of Focal Moderate Cardiac Allograft Rejection
Is Treatment Warranted?
From the Department of Pathology (G.L.W., F.J.S.) and Cardiovascular Division, Department of Medicine (E.L.), Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Background The rate of progression and potential long-term consequences of isolated foci of moderate acute rejection (FMR) on endomyocardial biopsy (EMB) have not been defined; therefore, whether FMR necessitates augmented immunosuppression remains controversial.
Methods and Results At our institution, recipients with EMBs having FMR, defined as one or two isolated foci of cellular infiltrates with associated myocyte damage (International Society for Heart and Lung Transplantation [ISHLT] grade 2 and a subset of grade 3A), do not routinely receive intensified immunosuppression. Accordingly, to determine the outcome of untreated FMR, we reviewed 4398 EMBs (mean, 4.4 samples each) obtained after orthotopic heart transplantation in 208 consecutive recipients maintained on triple immunosuppressive therapy. The incidence of progression versus resolution of FMR, the time interval after transplantation when FMR was detected, and the relation of untreated FMR to recipient survival were analyzed. FMR categorized as one (n=312) or two (n=89) foci was present in 401 EMBs (9% of total) obtained 10 days to 7.5 years after transplantation from 149 recipients (72%). EMBs with FMR resolved without treatment in 341 of 401 (85%), and only 60 of 401 (15%) progressed to higher grade rejection. EMBs that progressed occurred 7.5±7.9 months (mean±SD) after transplantation compared with 14.0±16.5 months after transplantation for those that resolved (P<.005). Of the 60 EMBs that progressed, 55% occurred within the first 6 months, 78% within the first year, and 97% within the first 2 years after transplantation. EMBs with two foci of FMR were no more likely to progress than those with one focus. Thirty-nine recipients experienced one (n=25), two (n=9), three (n=3), or four (n=2) episodes of FMR that progressed. One or more episodes of FMR that did not progress occurred in 110 recipients. By Kaplan-Meier analysis, survival at 1 and 5 years was similar in recipients with and those without FMR progression.
Conclusions First, untreated FMR consisting of either one or two foci has a low rate of progression. Second, progression of FMR decreases with increasing postoperative interval and becomes rare after 2 years. Last, FMR progression did not identify recipients with decreased survival.
Key Words: biopsy • pathology • rejection • transplantation
This article has been cited by other articles:
 |
|
 |
|
  R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]
|
|
|
|
|
|
L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578. [Full Text]
|
|
|
|
 |
|
 T. Caus, F. Kober, P. Marin, A. Mouly-Bandini, J. Quilici, D. Metras, P. J. Cozzone, and M. Bernard Non-invasive diagnostic of cardiac allograft vasculopathy by 31P magnetic resonance chemical shift imaging Eur. J. Cardiothorac. Surg., January 1, 2006; 29(1): 45 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lietz, R. John, E. Burke, M. Schuster, T. B. Rogers, N. Suciu-Foca, D. Mancini, and S. Itescu Immunoglobulin M-to-Immunoglobulin G Anti-Human Leukocyte Antigen Class II Antibody Switching in Cardiac Transplant Recipients Is Associated With an Increased Risk of Cellular Rejection and Coronary Artery Disease Circulation, October 18, 2005; 112(16): 2468 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Schoen and R. F. Padera Jr. Cardiac Surgical Pathology Card. Surg. Adult, January 1, 2003; 2(2003): 119 - 185. [Full Text]
|
|
|
|
 |
|
 T. J. Dengler, R. Zimmermann, K. Braun, M. Muller-Bardorff, J.o. Zehelein, F.-U. Sack, P. A. Schnabel, W. Kubler, and H. A. Katus Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation J. Am. Coll. Cardiol., August 1, 1998; 32(2): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Jarcho and E. J. Mark Case 17-1998- A 53-Year-Old Man with Left Ventricular Dysfunction Four Years after a Heart Transplantation N. Engl. J. Med., May 28, 1998; 338(22): 1608 - 1616. [Full Text] [PDF]
|
|
|
|
 |
|
 N R B CARY Grading of cardiac transplant rejection Heart, May 1, 1998; 79(5): 423 - 424. [Full Text]
|
|
|
|
|
|
S K Suvarna, A Kennedy, F Ciulli, and T J Locke Revision of the 1990 working formulation for cardiac allograft rejection: the Sheffield experience Heart, May 1, 1998; 79(5): 432 - 436. [Abstract] [Full Text]
|
|
|
|
|
|
A. H Balk, P. E Zondervan, P. van der Meer, T. van Gelder, B. Mochtar, M. L Simoons, and W. Weimar Effect of adopting a new histological grading system of acute rejection after heart transplantation Heart, December 1, 1997; 78(6): 603 - 607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. B.-L. Rocca, G. Sutsch, J. Schneider, F. Follath, and W. Kiowski Natural Course of Moderate Cardiac Allograft Rejection (International Society for Heart Transplantation Grade 2) Early and Late After Transplantation Circulation, September 15, 1996; 94(6): 1334 - 1338. [Abstract] [Full Text]
|
|